Furano-1,2-naphthoquinone inhibits EGFR signaling associated with G2/M cell cycle arrest and apoptosis in A549 cells

Cell Biochemistry and Function

Volumn 28, Issue 8, 2010, Pages 695-705

  Su, J C ^a   Lin, K L ^a   Chien, C M ^a   Tseng, C H ^a   Chen, Y L ^a   Chang, L S ^b   Lin, S R ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

A549; Apoptosis; EGFR; JAK STAT; MAPK

Indexed keywords

1,2 NAPHTHOQUINONE DERIVATIVE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CASPASE 3; CASPASE 9; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; FURANO 1,2 NAPHTHOQUINONE; FURANONE DERIVATIVE; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CELL DIVISION; CELL PROLIFERATION; ENZYME ACTIVATION; FURANS; G2 PHASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JANUS KINASE 2; LUNG NEOPLASMS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHOQUINONES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 78649459636     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1710     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Raez LE, Lilenbaum R. Chemotherapy for advanced non-small-cell lung cancer. Clin Adv Hematol Oncol 2004; 2: 173-178.
3. Kelly K. The role of targeted agents in adjuvant therapy for non-small cell lung cancer. Clin Cancer Res 2005; 11: 5027s-5029s.
4. Steinke K. Lung tumors. Recent Results Cancer Res 2006; 167: 107-122.
5. Orren DK, Petersen LN, Bohr VA. Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis. Mol Biol Cell 1997; 8: 1129-1142.
6. Fujimoto K, Hosotani R, Doi R, et al. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cell. Int J Cancer 1999; 81: 637-644.
7. Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000; 60: 1426-1433.
8. Murray AW. Revisiting the cell cycle: cyclins revisited. Cell 2004; 116: 221-234.
9. Doree M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994; 8: 1114-1121.
10. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
11. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000; 256: 50-57.
12. Chipuk JE, Green DR. How do Bcl-2 proteins induce mitochondrial outer membrane permeabilization ? Trends Cell Biol 2008; 18: 157-164.
13. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-6406.
14. Bogdan S, Klambt C. Epidermal growth factor receptor signaling. Curr Biol 2001; 11: R292-R295.
15. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20: S1-S13.
16. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29: S3-S9.
17. Citri A, Yarden Y. EGF-ERB signaling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-516.
18. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 3153-3159.
19. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19: 2013-2023.
20. Rane SG, Reddy EP. Janus kinases components of multiple signaling pathways. Oncogene 2000; 19: 5662-5679.
21. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002; 2: 381-392.
22. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
23. Xia Z, Dickens M, Raingeaud J, Davis R, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
24. Klekotka PA, Santoro SA, Wang H, Zutter MM. Specific residues within the alpha 2 integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways. J Biol Chem 2001; 276: 32353-32361.
25. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997; 1333: F85-F104.
26. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor. J Biol Chem 1998; 273: 10232-10239.
27. Davis, RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
28. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 2001; 410: 37-40.
29. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912
30. Goulart MOF, Zani CL, Tonholo J, et al. Trypanocidal activity and redox potential of heterocyclic- and 2-hydroxy-naphthoquinines. Bioorg Med Chem Lett 1997; 7: 2043-2048.
31. Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 2005; 203: 124-131.
32. Kongkathip N, Kongkathip B, Siripong P, et al. Potent antitumor activity of synthetic 1, 2-naphoquinones and 1, 4-naphoquinones. Bioorg Med Chem 2003; 11: 3179-3191.
33. Chen YL, Chung CH, Chen IL, Chen PH, Jeng HY. Synthsis and cytotoxic activity evaluation of indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline derivatives. Bioorg Med Chem 2005; 10: 2705-2712.
34. Sutton DC, Gillan FT, Susic M. Naphthofuranone phytoalexins from the gray mangrove, Avicennia marina Phytochemistry 1985; 24: 2877-2879.
35. Lee YR, Kim BS, Jung YU, Koh WS, Cha JS, Kim NW. Facile synthesis of avicequinone-B natural product. Synth Commun 2002; 32: 3099-3105.
36. Tseng CH, Lin CS, Shi PK, et al. Furo[3', 2':3, 4]naphtha[1, 2-d]imidaxole derivatives as potential inhibitors of inflammatory factors in sepsis. Bioorg Med Chem 2009; 17: 6773-6779.
37. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-1788.
38. Zhu XF, Liu ZC, Xie BF, et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 2001; 169: 27-32.
39. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998; 273: 32111-32120.
40. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun-N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
41. Dudley DT, Pang L, Decker SJ, Bridges AL, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
42. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1991
43. Lewin B. Driving the cell cycle: M phase kinases, its partners, and substrates. Cell 1990; 61: 743-752.
44. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65-70.
45. Vousden KH, Lane, DP. p53 in health and disease. Nat Rev 2007; 8: 275-283.
46. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
47. Kuo PL, Ni EC, Tsai EM, Hsu YL. Dehydrocostuslactone disrupts signal transducers ans activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells. Mol Cancer Ther 2009; 8: 1328-1339.
48. Kurebayashi J, Okubo S, et al. Additive anti-tumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 2006; 58: 460-470.
49. Miyoshi N, Uchida K, Osawa T, Nakamura Y. A link between benzyle isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation. Cancer Res 2004; 64: 2134-2142.
50. Lin HH, Chen JH, Huang CC, Wang CJ. Apoptotic effect of 3, 4-dihydroxybenzoic acid on human gastric carcinoma cells involving JNK/p38 MAPK signaling activation. Int J Cancer 2007; 120: 2306-2316.
51. Ghatan S, Larner S, Kinoshita Y, et al. p38 MAP kinase mediates Bax translocation in nitric oxide-induced apoptosis in neuron. J Cell Biochem 2000; 150: 335-348.
52. Mandal C, Dutta A, Mallick A, et al. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 2008; 13: 1450-1464.
53. Xiao X, Wu J, Zhu X, et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007; 121: 2095-2104.
54. Gomathinayagam R, Sowmyalakshmi S, Mardhatillah F, Kumar R, Akbarsha MA, Damodaran C. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008; 28: 785-792.